← Back to Search

Vascular Access Device

Teleflex Arrowg+ard Blue Advanced Midline Catheter for Catheter-Associated Infections

N/A
Waitlist Available
Led By Amit Bahl, MD
Research Sponsored by William Beaumont Hospitals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days post line insertion
Awards & highlights

Summary

Peripherally inserted central catheters (PICCs) are central catheters that are placed via peripheral vein under ultrasound guidance and may be used for patients with difficult venous access for long-term central or peripheral infusion therapies as well as central venous pressure monitoring in a critical care setting. Although PICCs provide a great option for some patients, these catheters have known complications including catheter-related bloodstream infection, catheter-related venous thrombosis or clotting, malfunction, and high cost. Midline catheters represent a potentially attractive alternative to PICCs for peripheral infusions. As midlines have increased in popularity and new midlines have been introduced into the market, it is necessary to better understand complication profiles of various midline catheters, as it is likely that all catheters are not created equal. Specifically, the incidence of symptomatic catheter-related thrombosis is of interest. Some midline catheters are coated to provide protection against catheter-related venous thrombosis and/or catheter-related bloodstream infection. The theoretical benefit(s) of these catheters need further validation in human subjects.

Eligible Conditions
  • Catheter-Associated Infections
  • Catheter Thrombosis
  • Catheter Complications

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days post line insertion
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days post line insertion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Upper Extremity CR-UEVT
Secondary outcome measures
Line Related Infection
Other outcome measures
Catheter Survival

Trial Design

2Treatment groups
Active Control
Group I: Teleflex Arrowg+ard Blue Advanced Midline CatheterActive Control1 Intervention
Placement of clinically indicated Teleflex Arrowg+ard Blue Advanced Midline Catheter
Group II: Angiodynamics BioFlo Midline CatheterActive Control1 Intervention
Placement of clinically indicated Angiodynamics BioFlo midline catheter.

Find a Location

Who is running the clinical trial?

William Beaumont HospitalsLead Sponsor
150 Previous Clinical Trials
112,417 Total Patients Enrolled
TeleflexIndustry Sponsor
21 Previous Clinical Trials
4,633 Total Patients Enrolled
Amit Bahl, MDPrincipal InvestigatorWilliam Beaumont Hospitals
6 Previous Clinical Trials
1,087 Total Patients Enrolled
~32 spots leftby Sep 2025